The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials

Gerald Schulman; Tomás Berl; Gerald J. Beck; Giuseppe Remuzzi; Eberhard Ritz; Miho Shimizu; Yuko Shobu; Mami Kikuchi

doi:10.1186/s12882-016-0357-9

Shared by

Giuseppe Remuzzi

The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials

Article 2016 en

Authors

GS
Gerald Schulman
TB
Tomás Berl
GB
Gerald J. Beck

Abstract

1 min read

ClinicalTrials.gov NCT00500682 ; NCT00501046 .

Related publications

Article2017

Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120

Gerald Schulman, Tomás Berl, Gerald J. Beck, Giuseppe Remuzzi, Eberhard Ritz, Miho Shimizu, Mami Kikuchi, Yuko Shobu

Article2014

Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD

Gerald Schulman, Tomás Berl, Gerald J. Beck, Giuseppe Remuzzi, Eberhard Ritz, Kiyoshi Arita, Akira Kato, Miho Shimizu

Article2024

SHIFTING PARADIGMS: EXPLORING ENARODUSTAT FOR ANEMIA IN CHRONIC KIDNEY DISEASE IN A META ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Lokman Hekim Tanrıverdi, Ahmet Sarıcı

Preprint2020

Ticagrelor Monotherapy in Patients with Concomitant Diabetes Mellitus and Chronic Kidney Disease: A post Hoc Analysis of The GLOBAL LEADERS Trial

Chao Gao, Mariusz Tomaniak, Kuniaki Takahashi, Hideyuki Kawashima, Rutao Wang, Hironori Hara, Masafumi Ono, Gilles Montalescot, Scot Garg, Michael Haude, Ton Slagboom, Pascal Vranckx, Marco Valgimigli, Stephan Windecker, Robert-Jan van Geuns, Christian Hamm, Philippe Gabríel Steg, Yoshinobu Onuma, Dominick J. Angiolillo, Patrick W. Serruys

Research Square (Research Square)

Article2021

ALBI score and outcomes in patients with hepatocellular carcinoma: <i>post hoc</i> analysis of the randomized controlled trial KEYNOTE-240

Arndt Vogel, Philippe Merle, Chris Verslype, Richard S. Finn, Andrew X. Zhu, Ann‐Lii Cheng, Stephen L. Chan, Thomas Yau, Baek‐Yeol Ryoo, Jennifer J. Knox, Bruno Daniele, Shukui Qin, Ziwen Wei, Yanna R. Miteva, Usha Malhotra, Abby B. Siegel, Masatoshi Kudo

The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials

Abstract

Discussion(0)

Related publications

Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120

Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD

SHIFTING PARADIGMS: EXPLORING ENARODUSTAT FOR ANEMIA IN CHRONIC KIDNEY DISEASE IN A META ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Ticagrelor Monotherapy in Patients with Concomitant Diabetes Mellitus and Chronic Kidney Disease: A post Hoc Analysis of The GLOBAL LEADERS Trial

ALBI score and outcomes in patients with hepatocellular carcinoma: <i>post hoc</i> analysis of the randomized controlled trial KEYNOTE-240